RPL34P22

Across TCGA pan-cancer cohorts, RPL34P22 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RPL34P22’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL34P22 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL34P22 is over-expressed in tumor, although a few such as BRCA and LIHC show the opposite, repressed pattern.

BRCA, UCEC, and READ are the cancer types where RPL34P22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL34P22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	All	−0.247	<.001	6	view →
UCEC	All	II,III,IV	+0.176	.032	2	view →
READ	All	All	+0.290	.043	1	view →
CHOL	All	All	+0.215	.030	1	view →
COAD	All	II,III,IV	+0.115	.024	1	view →
LIHC	Male	All	−0.025	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RPL34P22–BRCA

Open the BRCA breakdown →